SALT LAKE CITY, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the United States Court of Appeals for the Federal Circuit declared that the Company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under Section 101 of the United States Patent Act. This decision reinstates the prior decision by the Court on July 29, 2011.
- "Gene" patents have not hindered research on BRCA 1 and BRCA 2 and Myriad has never denied, opposed or impeded any research studies on these, or any other , genes. Further, more than 18,000 scientists have researched the BRCA genes, publishing more than 9,000 research papers.
- The cost of the BRAC Analysis test is not prohibitive and patient access is extensive. Myriad has provided close to one million patients with BRAC Analysis test results. Approximately 95% of appropriate patients in the United States have access to BRAC Analysis either through private insurance, Medicare, Medicaid or Myriad's Financial Assistance Program, which provides coverage at no charge to low-income, uninsured patients. Over the past 3 years alone, more than 5,000 patients have benefitted from this assistance program.
- Lastly, second opinion testing is available for patients with positive test results in a number of U.S. laboratories, including a large reference laboratory licensed by Myriad in 2001.